In the case of various pathologies, an imbalance between ROS generation and the endogenous AOS can be observed, which leads to excessive ROS accumulation, intensification of LPO processes, and oxidative stress. For the prevention of diseases associated with oxidative stress, drugs with antioxidant activity can be used. The cytotoxic, antioxidant, and NO-donor properties of the new hybrid compound B6NO (di(3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridinium) salt of 2-(nitrooxy)butanedioic acid) were studied. It was determined that B6NO chelates iron ions by 94%, which indicates B6NO’s ability to block the Fenton reaction. The hybrid compound B6NO inhibits the process of initiated lipid peroxidation more effectively than pyridoxine. It was shown that B6NO exhibits antioxidant properties by decreasing ROS concentration in normal cells during the oxidative stress induction by tert-Butyl peroxide. At the same time, the B6NO antioxidant activity on tumor cells was significantly lower. B6NO significantly increases the intracellular nitrogen monoxide accumulation and showed low cytotoxicity for normal cells (IC₅₀ > 4 mM). Thus, the results indicate a high potential of the B6NO as an antioxidant compound.

中文翻译：

---

新型吡哆醇衍生物 B6NO 的制备、抗氧化性能和增加细胞内 NO 的能力

在各种病理情况下，可以观察到 ROS 生成与内源性 AOS 之间的不平衡，导致 ROS 过度积累、LPO 过程加剧和氧化应激。为了预防与氧化应激相关的疾病，可以使用具有抗氧化活性的药物。研究了新的杂化化合物 B6NO（2-（硝基氧基）丁二酸的二（3-羟基-4,5-双（羟甲基）-2-甲基吡啶鎓）盐）的细胞毒性、抗氧化和 NO 供体特性。经测定，B6NO 可螯合 94% 的铁离子，这表明 B6NO 具有阻断芬顿反应的能力。杂化化合物 B6NO 比吡哆醇更有效地抑制引发的脂质过氧化过程。过氧化叔丁基。同时，B6NO对肿瘤细胞的抗氧化活性显着降低。B6NO 显着增加细胞内一氧化氮的积累，对正常细胞的细胞毒性较低（IC ₅₀ > 4 mM）。因此，结果表明 B6NO 作为抗氧化剂化合物的潜力很大。